Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

BACKGROUND AND AIMS: Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Sang Hoon, Marcellin, Patrick, Ma, Xiaoli, Caruntu, Florin A., Tak, Won Young, Elkhashab, Magdy, Chuang, Wan-Long, Tabak, Fehmi, Mehta, Rajiv, Petersen, Jörg, Guyer, William, Jump, Belinda, Chan, Alain, Subramanian, Mani, Crans, Gerald, Fung, Scott, Buti, Maria, Gaeta, Giovanni B., Hui, Aric J., Papatheodoridis, George, Flisiak, Robert, Chan, Henry L. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244971/
https://www.ncbi.nlm.nih.gov/pubmed/30136045
http://dx.doi.org/10.1007/s10620-018-5251-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244971/
https://www.ncbi.nlm.nih.gov/pubmed/30136045
http://dx.doi.org/10.1007/s10620-018-5251-9

Ejemplares similares